Skip to main content

Table 3 Coronary dilations stratified by medications commonly prescribed to patients in obese or non-obese patients

From: Obesity and statins are both independent predictors of enhanced coronary arteriolar dilation in patients undergoing heart surgery

  BMI ≥ 30 BMI < 30
  Bradykinin response [10-8M] -% dilation (Std. Error) Bradykinin response [10-8M] -% dilation (Std. Error)
  (+) Drug (-) Drug P Value (+) Drug (-) Drug P Value
ACE inhibitor 63.5 (9.5) 51.0 (5.3) 0.237 33.5 (6.2) 58.2 (5.8) 0.007
Angiotensin receptor blocker 55.1 (6.1) 54.1 (7.2) 0.919 64.4 (8.1) 36.9 (5.1) 0.007
Aspirin 57.1 (4.8) 43.1 (14.6) 0.261 49.2 (5.3) 30.5 (9.2) 0.086
Statin 58.3 (4.7) 50.4 (8.6) 0.412 53.7 (5.1) 20.1 (6.0) 0.001
Insulin 48.3 (7.6) 56.3 (5.6) 0.492 57.9 (10.3) 41.3 (5.2) 0.165
Anti-diabetics 62.0 (23.0) 52.6 (5.1) 0.424 46.2 (11.5) 44.1 (5.3) 0.867
Beta blocker 89.3% of obese patients are on beta blockers; test not valid 51.5 (5.7) 34.8 (7.6) 0.081
Diuretic 50.3 (9.8) 55.8 (5.4) 0.641 52.3 (6.0) 38.9 (6.7) 0.166
Calcium channel blocker 55.8 (7.6) 53.5 (6.1) 0.811 38.6 (7.2) 49.2 (6.2) 0.267
H+ blocker 62.0 (6.8) 49.8 (62.6) 0.210 45.8 (7.9) 44.3 (5.5) 0.907
Nitrate 59.9 (8.6) 52.5 (5.7) 0.487 11.1% of non-obese patients are on nitrates; test not valid
  1. BMI – body mass index; ACE – angiotensin converting enzyme; ARB – angiotensin receptor blocker; CCB – calcium channel blocker, Significance determined by 1-Way ANOVA. Data is presented as the mean ± standard deviation.